# PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT CONTRACT

> **NIH NIH N01** · RESEARCH TRIANGLE INSTITUTE · 2022 · $76,466

## Abstract

The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA)
supports research and development of new medications for the treatment of drug addiction. The objective of this
contract is to provide NIDA and other NIH Institutes (NINDS and NIMH) with a a centralized confidential repository of
compounds for evaluation as potential treatment agents, standards and screening agents.

“This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management.”

## Key facts

- **NIH application ID:** 10723384
- **Project number:** 75N95022C00014-0-9999-2
- **Recipient organization:** RESEARCH TRIANGLE INSTITUTE
- **Principal Investigator:** KATIE HAYES
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $76,466
- **Award type:** —
- **Project period:** 2022-07-09 → 2023-07-08

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10723384

## Citation

> US National Institutes of Health, RePORTER application 10723384, PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT CONTRACT (75N95022C00014-0-9999-2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10723384. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*